Cargando…
Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data
PURPOSE: The effects of body mass index on pathologic complete response and survival have not been reported in Korean patients with breast cancer. The purpose of this study was to evaluate the predictive or prognostic value of obesity in breast cancer receiving neoadjuvant chemotherapy. METHODS: A t...
Autores principales: | Lee, Kyung-Hun, Keam, Bhumsuk, Im, Seock-Ah, Kim, Tae-Yong, Han, Sae-Won, Oh, Do-Youn, Kim, Jee Hyun, Lee, Se-Hoon, Han, Wonshik, Kim, Dong-Wan, Kim, Tae-You, Park, In Ae, Noh, Dong-Young, Heo, Dae Seog, Bang, Yung-Jue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Breast Cancer Society
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542851/ https://www.ncbi.nlm.nih.gov/pubmed/23346172 http://dx.doi.org/10.4048/jbc.2012.15.4.427 |
Ejemplares similares
-
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
por: Keam, Bhumsuk, et al.
Publicado: (2011) -
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
por: Keam, Bhumsuk, et al.
Publicado: (2007) -
Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
por: Keam, Bhumsuk, et al.
Publicado: (2011) -
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
por: Kim, Hee-Jun, et al.
Publicado: (2015) -
Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
por: Yang, Yaewon, et al.
Publicado: (2016)